Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
17 juil. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
09 juil. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Proof of Concept Now Established in Animal...
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
20 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...
Result of AGM
19 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Result of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 19 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM)...
Increased BARDA Award and Option Exercise
18 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
12 juin 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK,...
Notice of First Quarter Results
05 juin 2019 09h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 5 June 2019...
UK Annual Report and Notice of AGM
14 mai 2019 12h30 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Publication of UK Annual Report and Notice of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 14 May 2019 - Summit Therapeutics plc...
Block Listing Interim Review
29 avr. 2019 07h30 HE
|
Summit Therapeutics plc
BLOCK LISTING SIX MONTHLY RETURN (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 29 April 2019 Name of applicant:Summit Therapeutics plcName of scheme:2005 EMI...
Exercise of Restricted Stock Units
24 avr. 2019 11h20 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Exercise of Restricted Stock Units and Total Voting Rights Oxford, UK, and Cambridge, MA, US, 24 April 2019 – Summit Therapeutics plc (NASDAQ:...